RecruitingPhase 3NCT06615557
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Studying Polyrrhinia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- VistaGen Therapeutics, Inc.
- Intervention
- Fasedienol Nasal Spray(drug)
- Enrollment
- 236 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2027
Study locations (24)
- Vistagen Clinical Site, Phoenix, Arizona, United States
- Vistagen Clinical Site, Little Rock, Arkansas, United States
- Vistagen Clinical Site, Bellflower, California, United States
- Vistagen Clinical Site, Oceanside, California, United States
- Vistagen Clinical Site, Orange, California, United States
- Vistagen Clinical Site, Redlands, California, United States
- Vistagen Clinical Site, Torrance, California, United States
- Vistagen Clinical Site, Denver, Colorado, United States
- Vistagen Clinical Site, Tampa, Florida, United States
- Vistagen Clinical Site, Decatur, Georgia, United States
- Vistagen Clinical Site, Chicago, Illinois, United States
- Vistagen Clinical Site, Naperville, Illinois, United States
- Vistagen Clinical Site, Boston, Massachusetts, United States
- Vistagen Clinical Site, Bloomfield Township, Michigan, United States
- Vistagen Clinical Site, Flowood, Mississippi, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06615557 on ClinicalTrials.govOther trials for Polyrrhinia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT06846385Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic RhinitisShanghai Mabgeek Biotech.Co.Ltd
- RECRUITINGPHASE3NCT06834360A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsSanofi
- RECRUITINGPHASE3NCT06338995A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)Eli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06315426A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE2NCT06292923A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsTiziana Life Sciences LTD
- ACTIVE NOT RECRUITINGPHASE2NCT05891483Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal PolypsGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE3NCT04905901Nebulized Tranexamic Acid in Sinus SurgeryAssiut University